LumiThera Inc. to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)

SEATTLE, March 13, 2018 /PRNewswire/ — LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announces that Clark E. Tedford, Ph.D., Chief Executive Officer, is scheduled to present on Saturday, March 17, 2018 at 9:30 a.m. China Standard Time, at the 2018 Inaugural… Continue reading →

Posted on March 16th, 2018 in Press Releases | Comments Off on LumiThera Inc. to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)

LumiThera, Inc. to Participate in the 2018 Glaucoma 360 in San Francisco

SEATTLE, Feb. 5, 2018 /PRNewswire/ — LumiThera, a clinical stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will participate in the 7th Annual Glaucoma 360 New Horizons Forum being held on Friday, February 9, 2018 at The Palace Hotel, in San Francisco. This meeting… Continue reading →

Posted on February 5th, 2018 in Press Releases | Comments Off on LumiThera, Inc. to Participate in the 2018 Glaucoma 360 in San Francisco

LumiThera to Present at the Digital Medicine and MedTech ShowcaseTM Annual Conference on January 10, 2018

SEATTLE, Jan. 4, 2018 /PRNewswire/ — LumiThera a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will present at the Digital Medicine and MedTech ShowcaseTM 2018, to be held January 8-10 during the most important week in healthcare at the Parc 55… Continue reading →

Posted on January 5th, 2018 in Press Releases | Comments Off on LumiThera to Present at the Digital Medicine and MedTech ShowcaseTM Annual Conference on January 10, 2018

LumiThera Unveils LIGHTSITE I Dry AMD Clinical Interim Data

SEATTLE, November 7, 2017 /PRNewswire/ — LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced topline interim results from the LIGHTSITE I trial for treatment of dry age-related macular degeneration (AMD) trial utilizing its LT-300 device. The 30-subject pilot study funded from… Continue reading →

Posted on November 7th, 2017 in Press Releases | Comments Off on LumiThera Unveils LIGHTSITE I Dry AMD Clinical Interim Data

LumiThera Closes Series B Round of Financing

SEATTLE, October 31, 2017 /PRNewswire/ — LumiThera Inc., a clinical stage private medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has completed the Series B round of financing. The company raised $5.5M to support further development of its LT-300 device for the treatment for dry Age-related… Continue reading →

Posted on October 31st, 2017 in Press Releases | Comments Off on LumiThera Closes Series B Round of Financing

TORPA 1 and 2

A pilot clinical study lead by LumiThera founders from The Toronto and Oak Ridge Study of Photobiomodulation (TORPA) looked at the effect of photobiomodulation (PBM) in the treatment of dry AMD. The TORPA data for dry AMD patient’s showed clinically and statistically significant improvement in both visual acuity and contrast sensitivity. TORPA Clinical Study The… Continue reading →

Posted on September 7th, 2017 in Articles | Comments Off on TORPA 1 and 2

LumiThera Named Most Innovative And Promising Medtech & E-Health Company At Biovision 2017

SEATTLE, April 18, 2017 /PRNewswire/ — LumiThera® Inc., a clinical stage medical device company focused on delivering non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announced it has been awarded the prestigious “MOST INNOVATIVE AND PROMISING MEDTECH & E-HEALTH COMPANY” during Biovision 2017 in Lyon, France. Biovision is a high-level investor event connecting… Continue reading →

Posted on April 18th, 2017 in Press Releases | Comments Off on LumiThera Named Most Innovative And Promising Medtech & E-Health Company At Biovision 2017

Dry AMD Therapy Evolves with Photobiomodulation

Non-invasive photobiomodulation may help dry age-related macular degeneration by causing regression of drusen and improving retinal function with benefits in visual acuity and contrast sensitivity. By Lynda Charters; Reviewed by Graham Merry, MBBS, and Marion R. Munk, MD, PhD Photobiomodulation (PBM) may be a new non-invasive, light-based treatment for patients with dry age-related macular degeneration… Continue reading →

Posted on September 22nd, 2016 in Articles | Comments Off on Dry AMD Therapy Evolves with Photobiomodulation

LumiThera Presents Results of TORPA II Clinical Study at the Association for Research in Vision and Ophthalmology (ARVO) Conference

SEATTLE, May 5, 2016 /PRNewswire/ — LumiThera® Inc., a late stage developmental medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease today announced that Graham Merry, MBBS presented clinical data results from the TORPA II study in Dry Age-Related Macular Degeneration (AMD) subjects at the Association for Research in Vision… Continue reading →

Posted on May 6th, 2016 in Press Releases | Comments Off on LumiThera Presents Results of TORPA II Clinical Study at the Association for Research in Vision and Ophthalmology (ARVO) Conference

LumiThera Named Most Promising and Innovative Catalyzer Startup at BIOVISION 2016

SEATTLE, April 27, 2016 /PRNewswire/ — LumiThera ® Inc., a late-stage developmental medical device company creating a non-invasive photobiomodulation (PBM) treatment for ocular disorders and disease, today announced it has been awarded the prestigious “MOST PROMISING AND INNOVATIVE CATALYZER AWARD” during Biovision 2016, Lyon, France. Biovision is a high-level investor event connecting industrial partners, financial… Continue reading →

Posted on April 28th, 2016 in Press Releases | Comments Off on LumiThera Named Most Promising and Innovative Catalyzer Startup at BIOVISION 2016